CARsgen Therapeutics Holdings (HKSE:02171) 3-Year EBITDA Growth Rate : 15.30% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings 3-Year EBITDA Growth Rate?

CARsgen Therapeutics Holdings's EBITDA per Share for the six months ended in Dec. 2023 was HK$-0.65.

During the past 3 years, the average EBITDA Per Share Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of CARsgen Therapeutics Holdings was 15.30% per year. The lowest was -49.70% per year. And the median was -17.20% per year.

Competitive Comparison of CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.

CARsgen Therapeutics Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CARsgen Therapeutics Holdings (HKSE:02171) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CARsgen Therapeutics Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CRTHF:USA

Address

No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN

Website

https://www.carsgen.com

CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.

Executives

Guo Bingsen	2401 A concert party to an agreement to buy shares
Guo Huaqing	2101 Beneficial owner
Li Zonghai	2401 A concert party to an agreement to buy shares
Wang Huamao	2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Private Limited	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Yang Zhi	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited	2201 Interest of corporation controlled by you
Applied Biomaterial Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd.	2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd.	2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines